Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
GLSI: Analyst Target of $57 Points to +235% Upside Potential

GLSI: Analyst Target of $57 Points to +235% Upside Potential

Key Takeaways

  • The central price target of $57 is the arithmetic mean of two verified analyst price targets — $45 (Noble Financial) and $69 (H.C. Wainwright) — rounded to a clean level.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company with no product revenue, making its valuation heavily dependent on Phase III trial data.
  • Against a share price near $17, reaching $57 would require a rise of roughly 235%, a very large move for a small-cap developer.
  • The analyst target range of $45 to $69 is wide, reflecting genuine disagreement about the company's lead immunotherapy candidate and its probability of success.
  • The strongest supporting factor is the ongoing Flamingo-01 Phase III trial of GLSI-100 in HER2-positive breast cancer; the biggest risks are clinical failure, financing needs, and execution risk.
  • You can find Major News, Today's Price Move, a detailed Forecast, and Earnings information on additional pages, which offer a fuller picture of this ticker.
  • Explore Trending AI Robots to see AI-driven tools that monitor stocks and ETFs for changing market conditions.

Analyst Price Targets and Consensus View

Greenwich LifeSciences, Inc. (GLSI) carries only two current, attributable analyst price targets, so the $57 figure is not a broad Wall Street consensus but a simple average of those two views. H.C. Wainwright analyst Yi Chen reiterated a Buy rating and raised the target to $69 from $50 in July 2026. Noble Financial's Robert LeBoyer reiterated a Buy with a $45 target in June 2026. Averaging these gives $57, with a low-to-high range of $45 to $69.

The wide gap between the two targets reflects differing assumptions about the same core question: whether GLSI-100, the company's HER2 peptide immunotherapy, will succeed in its pivotal Flamingo-01 Phase III trial. Both firms rate the stock a Buy, but the higher target embeds a more optimistic view of eventual regulatory approval and commercial potential, while the lower target discounts more risk. Investors should treat $57 as a calculated midpoint, not a guarantee or an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Shares of GLSI closed at $13.76 on November 16, 2026, then surged in intraday trading the following session to roughly $17–$18 on news of poster presentations at the San Antonio Breast Cancer Symposium (SABCS). Using a price near $17, the move to the $57 central target represents an upside of approximately 235% — a very large move even for a volatile clinical-stage stock. The company's 52-week range is $7.78 to $34.10, and its market capitalization is only about $250 million, meaning the stock can swing sharply on limited news flow.

Greenwich LifeSciences has no revenue and reported a trailing-twelve-month net loss of roughly $22 million, with cash of about $8.9 million in its most recent quarter. That means the path to $57 is almost entirely a binary bet on clinical data and the company's ability to fund operations through key readouts.

What Could Support a Move Toward the Target

The central thesis is the Flamingo-01 Phase III trial evaluating GLSI-100, a combination of the GP2 peptide and GM-CSF, designed to prevent breast cancer recurrence in HER2-positive patients. Positive efficacy or safety data could materially revalue the stock, as could favorable updates presented at medical meetings such as SABCS. Additional supportive factors include analyst targets that sit far above the current price, a small float that can amplify upside on good news, and the company's demonstrated ability to raise capital through at-the-market share sales — it reported raising net proceeds of about $9.34 million in the first half of 2026 at an average price near $25, well above recent levels.

What Could Prevent the Target From Being Reached

The principal risk is clinical: if Flamingo-01 fails to meet its endpoints, or if safety signals emerge, the stock could fall sharply because there is no revenue base to cushion it. Financing is a second major constraint — with modest cash and ongoing losses, the company will likely need additional capital, which could dilute existing holders. Competition in breast cancer immunotherapy, regulatory hurdles, and the inherent uncertainty of Phase III trials all weigh on the outlook. Valuation compression in the broader biotech sector, or a shift in investor sentiment away from speculative small caps, could also hold the stock back regardless of company-specific progress.

Technical Levels and Market Structure

The stock's technical structure reflects a wide, volatile range. The 52-week high of $34.10, set in late January 2026, stands as a significant overhead resistance level and sits below the $57 target. The 52-week low of $7.78 marks durable support. Between these extremes, the recent rally from the $13–$14 area toward $18 suggests short-term momentum, but the stock remains well below its prior high, and the $57 target implies breaking far above both the psychological $50 level and the established trading range. From what I see, monitoring these levels with AI-driven pattern tools can add context to the setup.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, though the exact window varies by firm and neither of the two covering analysts publishes a precise date for achieving the target. Investors should monitor upcoming Flamingo-01 trial milestones and data readouts, additional medical meeting presentations, quarterly updates on cash runway and financing activity, and any revisions to the two analyst targets. Because this is a single-asset clinical story, interim enrollment updates, regulatory feedback, and partnership or licensing announcements are all likely to move the stock more than broader market conditions. I’m watching this closely as trial updates come in.

Final Assessment

The $57 central target for Greenwich LifeSciences is derived from just two analyst price targets spanning $45 to $69, and it implies a very large move of roughly 235% from a price near $17. The bull case rests almost entirely on the Flamingo-01 Phase III trial of GLSI-100, while the bear case emphasizes binary clinical risk, thin cash reserves, and potential dilution. The wide analyst range underscores genuine uncertainty. Whether GLSI can reach $57 depends on trial outcomes and financing that cannot be predicted with confidence, so investors should weigh the potential reward against the substantial risk and monitor clinical milestones closely.

Integrating AI Signals into Biotech Research

Tickeron's AI Daily Buy/Sell Signals help track shifts in volatile names like this by applying AI to technical and market data. I find it useful for layering objective signals alongside fundamental review of trial timelines and cash positions. This approach keeps the process disciplined without replacing core analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLSI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GLSI sees its Stochastic Oscillator recovers from oversold territory

On November 17, 2026, the Stochastic Oscillator for GLSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 54 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 78 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +12.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

GLSI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.592). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3992 Bluebonnet Drive
Phone
+1 832 819-3232
Employees
13
Web
https://www.greenwichlifesciences.com
Interact to see
Advertisement
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.